On November 16, 2021 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that management will present a company overview at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, Nov. 30 at 8:25 a.m. ET (Press release, PTC Therapeutics, NOV 16, 2021, View Source [SID1234595669]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live on the Events and Presentations page on the Investor section of PTC Therapeutics’ website at View Source and will be archived for 30 days following the presentation. It is recommended that users connect to PTC’s website several minutes prior to the start of the webcast to ensure a timely connection.

On November 16, 2021 Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, reported that the Company will present two abstracts at the 63rd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition, which will be held virtually and in-person in Atlanta, Ga. December 11-14, 2021 (Press release, Aptevo Therapeutics, NOV 16, 2021, View Source [SID1234595633]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the presentations are as follows:

Title: "Tolerability and Single Agent Anti-Neoplastic Activity of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory AML or MDS"
Lead Author: Justin M. Watts, M.D., Sylvester Comprehensive Cancer Center and University of Miami Health System, Miami, Florida
Date/Time: Monday, December 13, 2021, 6:00 PM-8:00 PM
Online Access: View Source

Title: "Risk and Severity of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436"
Lead Author: Tara L. Lin, M.D., University of Kansas Cancer Center, Westwood, Kansas
Date/Time: Monday, December 13, 2021, 6:00 PM-8:00 PM
Online Access: View Source

About APVO436
Overexpression of CD123 is the hallmark of many forms of leukemia. Aptevo’s lead proprietary drug candidate, APVO436 is a bispecific ADAPTIR that targets CD123 x CD3 and is designed to redirect the immune system of the patient to destroy leukemia cells expressing the target CD123 molecule on their surface. This antibody-like recombinant protein therapeutic is designed to engage both leukemia cells and T-cells of the immune system and bring them closely together to trigger a rapid and complete destruction of leukemia cells. APVO436 has been engineered using Aptevo’s proprietary and enabling bioengineering methods and is designed to reduce the likelihood and severity of an unintended and potentially harmful activation of the immune system. APVO436 has been engineered to stay in the blood circulation long enough to locate, bind with and destroy target leukemia cells. APVO436 has received orphan drug designation ("orphan status") for AML according to the Orphan Drug Act.

On November 15, 2021 Gate2Brain reported the company seeks capital to advance its first therapy (Press release, Gate2Brain, NOV 15, 2021, View Source [SID1234641091]). The Spanish biotechnology company has opened a bridge financing round of one million euros to carry out the "key trials" of its cancer therapy, which are prior to the clinical phase.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In 2022, the company plans to open another round of five million more euros , with which all regulatory and non-regulatory preclinical trials will be carried out, according to Meritxell Teixidó, CEO of the company, to PlantaDoce. Gate2Brain expects the human clinical trial to take place in 2024.

The Spanish biotechnology company develops a patented technology based on peptides with the aim of improving the effectiveness of therapies against childhood tumors. The most important characteristic of the start-up is that it is focused on overcoming the physiological obstacles inherent to the human body , such as the blood-brain barrier.

Gate2Brain plans that its technology will allow pharmaceutical companies to recover drugs that do not end up reaching the market

The first therapy of its technological platform, named G2B-002, is aimed at the treatment of rare pediatric solid tumors . This treatment "acts as a shuttle and facilitates the arrival of the drug to the tumor areas," explains Teixidó. The company’s approach combines expertise in oncology, rare diseases and pediatrics.

The Barcelona start-up also plans that its technology will allow pharmaceutical companies to recover medications that do not end up reaching the market due to the impossibility of reaching the brain. In this sense, the company’s CEO states that "98% of drug candidates are discarded because they do not pass the blood-brain barrier." The company is in contact with some pharmaceutical companies.

At the beginning of the year, Gate2Brain was looking for up to three million euros to reach the clinical trial and planned to open a financing round. The objective of this round was already to find the capital necessary to reach the clinical trial, although the company’s plans have been adapted to the new planning, which increases the economic volume, but lengthens the deadlines and divides the round into two stages .

The founders control the majority of the company’s shareholders

Gate2Brain has received support from the Mind The Gap Program, from the Botín Foundation, which has invested half a million euros in the project. The start-up also obtained support from the CaixaImpulse program, from the La Caixa Foundation, funding from the Agency for Management and University Research Grants (Agaur) and from Banc Sabadell. In total, the company has raised 600,000 euros so far .

The founders control the majority of the company’s shareholders. Gate2Brain has been created by researchers from IRB Barcelona, ​​the University of Barcelona and the Sant Joan de Déu Research Institute. The company has its headquarters in the Barcelona Science Park .

On November 15, 2021 Carsgen Therapeutics reported that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to CT041, an autologous CAR T-cell product candidate against the claudin18.2 protein (CLDN18.2) for the treatment of gastric/gastroesophageal junction cancer (GC/GEJ) (Press release, Carsgen Therapeutics, NOV 15, 2021, View Source [SID1234618646]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of this announcement, CT041 is the only CLDN18.2-targeted CAR T-cell product candidate globally that is being studied in clinical trials with IND approvals from both the FDA and the NMPA. Also, CT041 is the first solid tumor CAR T-cell product to be granted PRIME eligibility. CARsgen is currently the only company with two CAR T-cell products active in the PRIME scheme.

"Access to PRIME support and enhanced interaction with EMA is an important milestone in accelerating the development and commercialization of CT041 CAR T cells," said Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen. "We believe that CT041 has the potential to become a backbone therapy for gastric/gastroesophageal junction cancer and pancreatic cancer in the future. With the mission of ‘making cancer curable,’ we will continue our efforts to develop more innovative technologies and products for cancer patients worldwide."

About CT041

CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first in its class globally. CT041 targets the treatment of CLDN18.2-positive solid tumors with a primary focus on GC/GEJ and pancreatic cancer (PC). CT041 has demonstrated promising therapeutic efficacy and favorable safety in ongoing clinical trials.

In addition to the investigator-initiated trials in China, CARsgen has initiated a Phase Ib/II clinical trial for advanced GC/GEJ and PC in China and a Phase 1b clinical trial for advanced gastric or pancreatic adenocarcinoma in the United States. CT041 received Orphan Drug designation for the treatment of GC/GEJ from the U.S. FDA in 2020 and Orphan Medicinal Product designation for the treatment of gastric cancer from the EMA in 2021. CARsgen has applied to the NMPA for the required regulatory approval for initiating the pivotal Phase II clinical trial in China. CARsgen also intends to conduct a pivotal Phase 2 clinical trial in North America in 2022.

About PRIME

PRIME is a scheme operated by the EMA to support the development of medicines that target an unmet medical need. Through PRIME, EMA offers early and proactive support to medicine developers to optimize the generation of robust data and enable accelerated assessment of medicine applications.

The PRIME scheme helps patients to benefit as early as possible from treatments that may significantly improve their quality of life. To be accepted for PRIME, a medicine must show its potential to offer a major therapeutic advantage over existing treatments, or to benefit patients without treatment options.

On November 15, 2021 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, reported that the Company has expanded its Intellectual Property ("IP") portfolio (Press release, Theralase, NOV 15, 2021, View Source [SID1234596745]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Theralase has recently been granted an Indian patent for, "Metal-Based Coordination Complexes as Photodynamic Compounds and their Use".

This patent encompasses numerous Theralase’s PDCs destined for the Indian market; most importantly, TLD-1433, which is currently under clinical investigation in a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study, being conducted in Canada and the United States.

The Mechanism of Action ("MOA") of the patented Theralase PDCs involves localization of the PDC inside the cancer cells of interest and then activating it by laser light to produce radical singlet oxygen and Reactive Oxygen Species ("ROS"), temporally and spatially to destroy the cancer cells, with minimum impact on healthy cells.

This patent further strengthens the extensive portfolio of patents already held by Theralase, by differentiating TLD-1433 cancer therapy versus its competitors and providing Theralase, a sustainable first-mover competitive advantage in PDC technology, in the oncology market. Theralase is focused on increasing shareholder value, by providing the Company international patents to protect its unique technology, as the Company moves closer towards commercialization.

Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer ("CEO") and Chief Scientific Officer ("CSO"), Theralase stated that, "This patent is strategic to opening up new international opportunities for Theralase by expanding its IP portfolio of medical laser and oncology focused technologies internationally. Theralase’s long-term strategy is to commercialize the Anti-Cancer Therapy ("ACT") division technology commencing with NMIBC and expanding into Glio Blastoma Multiforme ("GBM"), Non-Small Cell Lung Cancer ("NSCLC") and other various cancer indications to provide a safe, effective and rapid alternative treatment option for patients inflicted with these deadly diseases. The ability to provide personalized treatment for cancer patients to "hunt and destroy" their cancer and prevent its recurrence and progression, all in a single or dual treatment, remains at the forefront of our research and development objectives".